Newer uses of intravenous immunoglobulins as anti-infective agents

Pennington, James E.

doi:10.1128/aac.34.8.1463

Cited by 20 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…infection model could provide an useful system for the testing of such compounds. Anti-C. neoformans antibodies may also be useful for prophylaxis of high-risk groups, and the feasibility of such a strategy is supported by the successful use of passive immunoglobulin to prevent infection in pediatric AIDS patients (62). MAbs 2H1 and 2D10, or their derivatives (76), are potential candidates for use in human treatment and prevention trials.…”

Section: Discussionmentioning

confidence: 99%

Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice

et al. 1994

View full text Add to dashboard Cite

Immunoglobulin Gl (IgGl) monoclonal antibodies (MAbs) to the capsular glucuronoxylomannan (GXM) were studied for their ability to modify the course of intravenous Cryptococcus neoformans infection in mice. A/J mice were given intraperitoneal injection of 1.0 mg of either a GXM-binding IgGl MAb (2H1 or 2DlOyl) or the irrelevant isotype-matched control MAb 36-65 prior to intravenous infection. Parameters used to study antibody efficacy were lung and brain tissue fungal burden, lung and brain weights, serum GXM levels, and histopathological examination of lung, brain, heart, kidney, and spleen tissues. Mice given GXM-binding MAb had significantly reduced lung tissue fungal burden as measured by CFU. In contrast to the reduction in lung tissue burden, the reduction in brain tissue burden was small and did not achieve statistical significance. Serum GXM levels were reduced in mice receiving GXM-binding MAb. Histopathological examination revealed reduced numbers of granulomas and C. neofornans organisms in the lungs, brains, and kidneys of MAb 2H1-treated mice relative to control mice. The lungs and brains of mice receiving GXM-binding MAb weighed significantly less than those of control animals, consistent with the reduced inflammation noted histologically. Subendocardial inflammation and kidney cortical infarctions were present in control infected mice but not in MAb 2H1-treated mice. Immunocytochemical staining for polysaccharide antigen revealed a marked reduction in the amount of tissue polysaccharide in mice treated with MAb 2H1 relative to control mice. The results support an useful role for passive antibody administration in C. neoformans infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice

et al. 1994

View full text Add to dashboard Cite

show abstract

“…In addition, passive antibody could have a role in the prevention of C. neoformans infections in high-risk groups. In this regard, passive polyclonal antibody is already used prophylactically with considerable success in the prevention of infection in children with AIDS, indicating that prophylactic approaches are feasible in targeted populations (42). Passive antibody offers a means of enhancing existing antifungal chemotherapy in the setting of severe immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B

Mukherjee

Zuckier

Scharff

et al. 1994

Antimicrob Agents Chemother

136

104

View full text Add to dashboard Cite

show abstract

“…The clinical management of V. vulnificus septicemia and wound infections involves appropriate antibiotic therapy and, in wound infections, removal of necrotic tissues. Passive immunization with hyperimmune globulins to capsular polysaccharides has been successfully used in the treatment of systemic infections caused by Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis (24,30). Passive administration of antibodies is a potential adjunctive therapeutic option for the prophylaxis and treatment of V. vulnificus septicemia.…”

mentioning

confidence: 99%

Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus

et al. 1996

View full text Add to dashboard Cite

Vibrio vulnificus is an oyster-associated bacterial pathogen that causes life-threatening fulminating septicemia and necrotizing wound infections in humans. The capsular polysaccharide of V. vulnificus (VvPS) is critical for virulence. Previously we showed that active immunization of mice with a VvPS-tetanus toxoid (VvPS-TTa) conjugate vaccine conferred significantly higher protection against subsequent lethal challenge than immunization with VvPS alone. In the current study, we examined the utility of immunoprophylaxis or immunotherapy with hyperimmune antisera elicited by VvPS-TTa and VvPS-TTb conjugate vaccines prepared by different synthetic schemes. First we demonstrated that the Ribi adjuvant significantly enhanced the murine antibody response (P < 0.02) to both conjugates. Subsequently, high-titered polyclonal antisera were raised to VvPS-TTa and VvPS-TTb conjugate vaccines by using Ribi adjuvant or Freund's adjuvants. Antisera were observed to have protective effects when administered before and after acute lethal infection. All animals receiving prophylactic antisera intraperitoneally 24 h before lethal challenge with homologous carbotype 1 were protected, while 73 to 100% of control mice succumbed. Immunotherapy was also effective, with survival rates of 60 to 73% seen among mice when antisera were administered 2 h after bacterial challenge, at a time when symptoms of infection were already apparent. The protective effect of capsular antiserum appeared to be serotype specific. Antisera to the carbotype 1 VvPS-TTa vaccine did not confer cross-protection against lethal challenge with carbotype 2 V. vulnificus despite partial structural similarity and a weak serological crossreaction between the two carbotypes. Immune globulins induced by a potential multivalent VvPS conjugate vaccine composed of clinically prevalent carbotypes may have utility in the management of V. vulnificus infections and deserve further evaluation.

show abstract

Newer uses of intravenous immunoglobulins as anti-infective agents

Cited by 20 publications

References 31 publications

Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice

Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice

Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B

Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus

Contact Info

Product

Resources

About